[Studies on retrograde amnesia in petit mal].

A. Jus,K. Jus

1961-07-01

Abstract:

What problem does this paper attempt to address?

Journal Watch of Neural systems subserving valence and arousal during the experience of induced emotions

T. Colibazzi

DOI: https://doi.org/10.1177/0003065113484061

IF: 0.919

2013-04-01

Journal of the American Psychoanalytic Association

Abstract:Moreover, it would suggest that the self-hatred in depression is not “anger turned against the self ” but the absence of anger relative to guilt. The study did indeed show that patients with depression in remission showed decreased coupling of the SCSR and the ATL; thus, they cannot activate the neural processes that allow a person to have differential experiences of guilt and anger at others. Perhaps more interesting to us as psychoanalysts is that across all subjects, normal controls and patients with remitted depression combined, the degree of uncoupling of the ATL and the SCSR correlated with self-hatred scores. Thus, the illumination of how this neural network functions explains more than just the symptoms of depression; it is consistent with what we see in patients—some feel more guilty than others. However, it also suggests that the dynamic construction that guilt and anger are invariably two sides of the same coin may not hold. The authors’ conclusion that “the results of this study point to a functional disconnection mechanism that is compatible with the known interaction of psychosocial learning and heritable neurobiological factors in the pathogenesis of major depression” is understandably focused on the sample of depressed patients. However, the data permit extension of this concept to nondepressed patients as well. So what are we to take from this study? First, some analysts, perhaps many, believe that studies of how the brain functions are not relevant for psychoanalysts, who are trying to understand the complexities of how the unconscious and conscious mind works because imaging studies are simplistic and reductionistic. However, as the technology advances and we are able to ask more complicated questions, this problem is attenuated; this study is certainly evidence of this progress. Second, patients who are preoccupied with guilt, self-blame, or self-hatred may in fact not experience, consciously or unconsciously, hatred of others, not even of the analyst, but only of themselves.
Acupuncture for Treatment of Arthralgia Secondary to Aromatase Inhibitor Therapy in Women with Early Breast Cancer: Pilot Study

B Oh,B Kimble,D S J Costa,E Davis,A McLean,K Orme,J Beith

DOI: https://doi.org/10.1136/acupmed-2012-010309

2013-09-01

Acupuncture in Medicine

Abstract:Background Aromatase inhibitors (AIs) are recommended as adjuvant hormone treatment for postmenopausal women with early breast cancer. A substantial proportion of women taking AIs experience joint pain and stiffness. Studies have suggested that acupuncture may be effective in treating joint pain. Objective A pilot study was conducted to evaluate the feasibility, safety and efficacy of using acupuncture to treat AI-induced arthralgia. Methods A total of 32 patients were randomised to receive either sham or real electroacupuncture (EA) twice weekly for 6 weeks. Outcomes of joint pain, stiffness and physical function were measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), overall pain severity and interference with the BPI-SF and quality of life (QOL) with the Functional Assessment of Cancer Therapy-General (FACT-G) instrument. Hand strength was assessed by a grip test, and a serum marker of inflammation (C reactive protein (CRP)) was also measured. All assessments were performed at baseline, 6 weeks and 12 weeks, except for blood samples at baseline and 6 weeks only. Results No serious adverse events were reported during or after acupuncture treatments. There were no significant differences in outcome measures. However, positive trends were observed in stiffness and physical function at week 12 in favour of real EA. Conclusions Findings suggest that acupuncture is feasible and safe in patients with breast cancer with joint pain caused by AI. A larger study with adequately powered to confirm these results and detect clinically relevant effects is needed.

integrative & complementary medicine
Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients

Katherine D. Crew,Jillian L. Capodice,Heather Greenlee,Arlyn Apollo,Judith S. Jacobson,George Raptis,Kimberly Blozie,Alex Sierra,Dawn L. Hershman

DOI: https://doi.org/10.1007/s11764-007-0034-x

2007-10-12

Journal of Cancer Survivorship

Abstract:IntroductionAromatase inhibitors (AIs) have become the standard of care for the adjuvant treatment of postmenopausal, hormone-sensitive breast cancer. However, patients receiving AIs may experience joint symptoms, which may lead to early discontinuation of this effective therapy. We hypothesize that acupuncture is a safe and effective treatment for AI-induced arthralgias.MethodsPostmenopausal women with early-stage breast cancer who had self-reported musculoskeletal pain related to adjuvant AI therapy were randomized in a crossover study to receive acupuncture twice weekly for 6 weeks followed by observation or vice-versa. The intervention included full body and auricular acupuncture, and a joint-specific point prescription. Outcome measures included the Brief Pain Inventory-Short Form (BPI-SF), Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index, the Functional Assessment of Cancer Therapy-General (FACT-G) quality of life measure, and serum levels of inflammatory markers, IL-1β and TNF-α.ResultsTwenty-one women were enrolled and two discontinued early. From baseline to the end of treatment, patients reported improvement in the mean BPI-SF worst pain scores (5.3 to 3.3, p = 0.01), pain severity (3.7 to 2.5, p = 0.02), and pain-related functional interference (3.1 to 1.7, p = 0.02), as well as the WOMAC function subscale and FACT-G physical well-being (p = 0.02 and 0.04, respectively). No adverse events were reported.Discussion/conclusionsIn this pilot study, acupuncture reduced AI-related joint symptoms and improved functional ability and was well-tolerated.Implications for cancer survivorsMusculoskeletal side effects are common among breast cancer survivors on adjuvant AI therapy, therefore, effective treatments are needed for symptom relief and to improve adherence to these life-saving medications.

oncology,social issues
Yoga versus massage in the treatment of aromatase inhibitor-associated knee joint pain in breast cancer survivors: a randomized controlled trial

Chia-Lin Tsai,Liang-Chih Liu,Chih-Ying Liao,Wen-Ling Liao,Yu-Huei Liu,Ching-Liang Hsieh

DOI: https://doi.org/10.1038/s41598-021-94466-0

IF: 4.6

2021-07-21

Scientific Reports

Abstract:Abstract Aromatase inhibitors (AIs) are standard adjuvant therapy for postmenopausal women with oestrogen receptor-positive, early-stage, and metastatic breast cancer. Although effective, the risk of falls due to AI-associated knee joint pain significantly increased. The aim of this study was to evaluate the therapeutic effects of yoga and massage on AI-associated knee joint pain. Breast cancer survivors were randomly assigned to a 6-week yoga intervention-2-week rest-6-week massage exposure (Yoga first, n = 30) or a 6-week massage intervention-2-week rest-6-week yoga exposure (Massage first, n = 30). Evaluations of the treatment efficacy were made at baseline, post-intervention, and post-exposure using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale, plasma cytokine levels, and changes in meridian energy. The results showed that yoga, superior to massage intervention, significantly reduced AI-associated knee joint pain, as demonstrated by the WOMAC pain score. The yoga intervention improvements were also associated with changes in plasma cytokine levels and meridian energy changes. In conclusion, this study provides scientific evidence that yoga was more effective than massage for reducing AI-associated knee joint pain. Meridian energy changes may provide another scientific, objective, non-invasive way to monitor the therapeutic effects of yoga and investigate another alternative, complementary medicine.

multidisciplinary sciences
Multiple Sclerosis Therapy

B. W. Oosten,Luc Truyen,F. Barkhof,C. Polman

DOI: https://doi.org/10.2165/00003495-199549020-00005

1995-02-01

Drugs

Abstract:
Suppressing effects of caffeine on postextrasystolic potentiation in papillary muscles of guinea pigs.

J. Asayama,T. Tatsumi,H. Miyazaki,I. Omori,D. Inoue,M. Nakagawa

DOI: https://doi.org/10.1253/JCJ.54.207

1990-02-20

Japanese Circulation Journal

Abstract:It is well known that the strength of postextrasystolic potentiation (PESP) is dependent on the prematurity of the ectopic beat, though the fundamental mechanism of the potentiation is still obscure. In this study, the effect of a resting interval on the strength of PESP was investigated in isolated papillary muscles of guinea pigs in the presence or absence of caffeine, which inhibits the functions of sarcoplasmic reticulum (SR). PESP of a fixed coupling interval increased and then decreased as the resting interval was prolonged. The maximum of PESP was obtained at a resting interval of 3 to 4 sec. The dependency of PESP on a coupling interval was decreased considerably by 5 x 10(-4) M caffeine and removed completely by 10(-2) M caffeine. Although 5 x 10(-4) M caffeine decreased the degree of contraction of postextrasystole, the maximum contraction of postextrasystole was still obtained at a resting interval of 3 to 4 sec. After the application of 10(-2) M caffeine, the postextrasystolic contraction gradually declined as the resting interval was prolonged. We conclude that SR Ca release contributes largely to a mechanism of PESP and increases in contribution as the coupling interval of an extrastimulation shortens, and that the optimal resting interval is determined by a balance between the activity of SR function and the activity of the sarcolemmal Ca extrusion mechanism.
Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial

Dawn L Hershman,Joseph M Unger,Heather Greenlee,Jillian Capodice,Danika L Lew,Amy Darke,Lori M Minasian,Michael J Fisch,N Lynn Henry,Katherine D Crew

DOI: https://doi.org/10.1001/jamanetworkopen.2022.41720

2022-11-01

Abstract:Importance: Aromatase inhibitors (AIs) have proven efficacy for the treatment of hormone-sensitive breast cancer; however, arthralgias (pain and stiffness) contribute to nonadherence with therapy for more than 50% of patients. Objective: To examine the effect of acupuncture in reducing AI-related joint pain through 52 weeks. Design, setting, and participants: A randomized clinical trial was conducted at 11 sites in the US from May 1, 2012, to February 29, 2016, with a scheduled final date of follow-up of September 5, 2017, to compare true acupuncture (TA) with sham acupuncture (SA) or waiting list control (WC). Women with early-stage breast cancer were eligible if they were taking an AI and scored 3 or higher on the Brief Pain Inventory Worst Pain (BPI-WP) item (score range, 0-10; higher scores indicate greater pain). Analysis was conducted for data received through May 3, 2021. Interventions: Participants were randomized 2:1:1 to the TA (n = 110), SA (n = 59), or WC (n = 57) group. The TA and SA protocols were composed of 6 weeks of intervention at 2 sessions per week (12 sessions overall), followed by 6 additional weeks of intervention with 1 session per week. Participants randomized to WC received no intervention. All participants were offered 10 acupuncture sessions to be used between weeks 24 and 52. Main outcomes and measures: In this long-term evaluation, the primary end point was the 52-week BPI-WP score, compared by study group using linear regression, adjusted for baseline pain and stratification factors. Results: Among 226 randomized women (mean [SD] age, 60.7 [8.6] years; 87.7% White; mean [SD] baseline BPI-WP score, 6.7 [1.5]), 191 (84.5%) completed the trial. In a linear regression, 52-week mean BPI-WP scores were 1.08 (95% CI, 0.24-1.91) points lower in the TA compared with the SA group (P = .01) and were 0.99 (95% CI, 0.12-1.86) points lower in the TA compared with the WC group (P = .03). In addition, 52-week BPI pain interference scores were statistically significantly lower in the TA compared with the SA group (difference, 0.58; 95% CI, 0.00-1.16; P = .05). Between 24 and 52 weeks, 12 (13.2%) of TA, 6 (11.3%) of SA, and 5 (10.6%) of WC patients reported receipt of acupuncture. Conclusions and relevance: In this randomized clinical trial, women with AI-related joint pain receiving 12 weeks of TA had reduced pain at 52 weeks compared with controls, suggesting long-term benefits of this therapy. Trial registration: ClinicalTrials.gov Identifier: NCT01535066.
Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer

Gabriella Martino,Antonino Catalano,Rita Maria Agostino,Federica Bellone,Nunziata Morabito,Carmen Giulia Lasco,Carmelo Mario Vicario,Peter Schwarz,Ulla Feldt-Rasmussen

DOI: https://doi.org/10.1371/journal.pone.0230681

IF: 3.7

2020-03-26

PLoS ONE

Abstract:Introduction: Aromatase inhibitors (AIs) dramatically increased breast cancer (BC) survival, leading to enhanced attention to their long-term consequences on psychological functioning. Conflicting data has been examined regarding the association between AIs administration and the clinical psychological features in BC survivors (BCSs). Purpose: As psychological symptoms often occur in such chronic diseases, our study aimed at exploring anxious and depressive symptoms and the perceived quality of life (QoL) in BCSs assessed for osteoporosis. Methods: The total sample consisted of a clinical sample of 51 outpatient postmenopausal women, diagnosed with BC, and a control group composed of 51 healthy postmenopausal women. All recruited participants were evaluated through the clinical gold standard interview and completed the following self-rating scales: the Hamilton Anxiety Rating Scale, Beck Depression Inventory II edition, and 36-Item Short Form Health Survey, which were administered at baseline and after 6 months in BCSs in AIs treatment, compared with controls. Moreover, all participants were assessed for vitamin D status, bone mineral density (BMD) and subclinical vertebral fractures. Data regarding age, age at menopause, body mass index (BMI), smoking habits and alcohol consumption was collected. Results: BCSs (n = 51) showed higher anxious and depressive symptoms, and lower perceived QoL vs. controls (n = 51) (p<0.05 for all). After 6 months of treatment with AIs, BCSs showed significant reduction of anxious and depressive symptoms and a significantly higher perceived QoL for both physical and mental components, vs. controls. Conclusions: The improvement of clinical psychological features and perceived QoL was associated with AIs treatment in women being treated with, for early breast cancer. Further studies are needed to obtain a deeper comprehension of the correlation between clinical psychological and physical features in BCSs.
Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial

Maryam Lustberg,Patty Fan-Havard,F. Lennie Wong,Kasey Hill,Mitch A. Phelps,Kevin W. Herrera,Ni-Chun Tsai,Timothy Synold,Ye Feng,Chidimma Kalu,Mina S. Sedrak,Lisa D. Yee

DOI: https://doi.org/10.1007/s10549-023-07223-4

2024-01-27

Breast Cancer Research and Treatment

Abstract:Abstract Purpose Aromatase inhibitor (AI) therapy reduces risk of recurrence and death for postmenopausal women with breast cancer (BC); however, AI-induced arthralgia (AIIA) can lead to discontinuation of treatment. Curcumin, a bioactive polyphenolic substance, may help ameliorate inflammation-related conditions including osteoarthritis and pain. Methods We conducted a multisite randomized placebo-controlled, double-blind pilot trial (Alliance A22_Pilot9) to evaluate the effects of nanoemulsion curcumin (NEC, 200 mg/day) in postmenopausal women experiencing AIIA for ≥ 3 months. The primary objective was to determine the feasibility of using Functional Assessment of Cancer Treatment-Endocrine Symptoms (FACT-ES) to detect changes from 0 (T0) to 3 months (T3) of NEC treatment in AI-induced symptoms and well-being; secondary objectives included evaluation of changes in Disabilities of the Shoulder, Arm, and Hand (DASH), Brief Pain Inventory-short form (BPI-SF), grip strength, and biomarkers at T0 and T3. Results Forty-two patients were randomized to NEC or placebo; 34 women completed the 3-month study. Patient-reported outcome measures (PROMs: FACT-ES, DASH, BPI-SF) and biospecimens were collected at T0-T3 in > 80% of participants. Adherence was ≥ 90% for both arms. PROMs and grip strength did not differ significantly by treatment arm. Plasma curcumin was detected only in NEC arm participants. Serum estradiol and estrone levels were below detection or low on study agent. Gastrointestinal adverse effects were commonly reported in both arms. Conclusion NEC versus placebo in a multisite randomized trial is feasible and well-tolerated. Additional studies with larger sample size are needed to further evaluate the efficacy and safety of NEC in treatment of AIIA. ClinicalTrials.gov Identifier: NCT03865992, first posted March 7, 2019.

oncology
Aromatase inhibitor musculoskeletal toxicity (AIMT) in patients (pts) with early breast cancer (EBC): Prevalence, management, and association with non-adherence to AI.

Pietro Lapidari,Maryam B. Lustberg,Julie Havas,Martina Pagliuca,Maria Alice B Franzoi,Gwenn Menvielle,Barbara Pistilli,Christelle Jouannaud,Baptiste Sauterey,Olivier Tredan,Paul H. Cottu,Christelle Levy,Florence Lerebours,Sibille Everhard,Anne-Laure Martin,Ines Maria Vaz Duarte Luis,Antonio Di Meglio

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.12122

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:12122 Background: AIMT may lead to treatment discontinuation and detriment on clinical outcomes in pts with EBC. Recommended supportive care (SC) management include adequate physical activity (PA) levels, acupuncture, and physical therapy. Reasonable pharmacologic approaches include duloxetine use and switching AI. We assessed prevalence of AIMT, SC use, and non-adherence to AI. Methods: Postmenopausal pts with EBC treated with adjuvant AI were included from the longitudinal CANTO cohort (NCT01993498). AIMT was defined as any grade (G) articular or muscular pain (CTCAE v4.0) after 3-6 months (Y0), 1 (Y1), 3 (Y3) and 5 years (Y5) of AI. Non-pharmacologic SC included adherence to PA recommendations (≥10 MET-h/week), consulting with an acupuncturist, physical therapist, or osteopath. Pharmacological SC included use of duloxetine, oral complementary-alternative medicine (OCAM), and switching to a different AI. Non-adherence was defined as any interruption and/or permanent discontinuation of AI. Multivariable logistic regressions tested associations of reporting AIMT with subsequent SC use and with non-adherence to AI. Results: Among 4854 pts, 85.9% reported AIMT overall (G3 17.5%): 61.0% at Y0 (G3 9.9%), 68.5% at Y1 (G3 8.7%), 65.4% at Y3 (G3 9.0%), and 57.0% at Y5 (G3 8.8%). Pts with AIMT were younger, with higher rate of previous musculoskeletal problems, and more frequently received chemotherapy. First and second prescribed AIs were mostly letrozole (54%) and exemestane (56%), respectively. Pts reporting AIMT at Y0 were less likely, by Y1, to adhere to PA recommendations (59.3% vs 62.6%), and slightly more likely to consult with an acupuncturist (9.0% vs 7.6%), physical therapist (46.0% vs 35.0%), or osteopath (22.4 vs 16.3%) compared to pts without AIMT. Results were consistent at remaining time-points. In multivariable models, reporting AIMT was consistently associated over time only with subsequent physical therapy consultations (adjusted [a]OR [95%CI]: Y1, 1.48 [1.24-1.78]; Y3, 1.40 [1.13-1.74]; Y5, 1.45 [1.10-1.91]), but not with other non-pharmacological SC. Only 1.4% of pts with AIMT reported duloxetine use, while 25.3% OCAM use. Switching AI was reported by 19.7% of pts with AIMT (aOR of AI switch vs no AIMT 2.47 [1.59-3.83]). 18.4% of pts reporting AIMT were non-adherent to AI: 6.0% had interruptions and 17.8% permanent discontinuations. Reporting overall AIMT was associated with non-adherence to AI (aOR vs no AIMT 2.38 [1.49-3.79]). Conclusions: Despite AIMT was highly prevalent and associated with non-adherence to AI in this prospective cohort, uptake of recommended SC strategies to manage AIMT seemed suboptimal and inconsistent over time. This large study highlights gaps in the implementation of guideline-concordant SC and warrants efforts to maximize treatment retention among pts with EBC treated with adjuvant AI.

oncology
Progressive relaxation training in patients with breast cancer receiving aromatase inhibitor therapy-randomized controlled trial

Umut Bahçacı,Songül Atasavun Uysal,Zeynep Erdogan İyigün,Çetin Ordu,Gürsel Remzi Soybir,Vahit Ozmen

DOI: https://doi.org/10.1371/journal.pone.0301020

IF: 3.7

2024-04-18

PLoS ONE

Abstract:Background Aromatase inhibitors have positive impacts on the disease-free life of patients with breast cancer. However, their side effects, especially arthralgia, may be experienced by many patients. This study sought to assess the efficacy of Progressive Relaxation Exercises on the prevalent side effects of Aromatase Inhibitors in patients with breast cancer. Materials and methods This clinical trial was conducted with single-blind randomization at a physiotherapy department in a local hospital. Patients who received Aromatase Inhibitor were assigned at random to either the study or control group. The study group (n = 22) performed a Progressive Relaxation Exercises program four days a week for six weeks, while the control group (n = 22) received advice on relaxation for daily life. Data was collected before the intervention and after six weeks. The study’s primary endpoint was the Brief Pain Inventory, which was used to measure pain severity. Secondary endpoints included assessments of quality of life and emotional status, which were measured using the Functional Assessment of Chronic Illness Therapy and Hospital Anxiety and Depression scales, respectively. Results The study group exhibited a significant reduction in Pain Severity (p = 0.001) and Pain Interference (p = 0.012) sub-scores. Reduction in Pain Severity (p 0.05). Conclusion The study demonstrated that Progressive Relaxation Exercises caused a significant reduction in pain scores among Breast Cancer patients receiving Aromatase Inhibitors. While a decrease in pain during the 6-week period is valuable data, it is necessary to monitor the long-term effects of relaxation techniques.

multidisciplinary sciences
Aromatase inhibitor-induced arthralgia ameliorated by Mediterranean diet and active lifestyle guided by continuous glucose monitoring: a case report and review of the literature

Kalin L. Wilson,Richard E. Grewelle,Tanya Gupta,Sun H. Kim,Tamiko R. Katsumoto

DOI: https://doi.org/10.3389/fonc.2024.1189287

IF: 4.7

2024-02-01

Frontiers in Oncology

Abstract:Aromatase inhibitors (AIs) are a cornerstone adjuvant treatment of many hormone receptor-positive breast cancers, and nearly half of women taking aromatase inhibitors suffer from AI-induced arthralgia (AIA), also known as AI-associated musculoskeletal syndrome (AIMSS), for which there are limited evidence-based treatments. Pharmacologic management and complementary methods including supplements, exercise, physical therapy, yoga, acupuncture, and massage have all shown mixed results. Comprehensive diet and lifestyle strategies are understudied in AIA/AIMSS despite their disease-modifying effects across many chronic conditions. Here we report a case of a woman with stage 2 estrogen and progesterone receptor-positive invasive ductal carcinoma on adjuvant anastrozole whose AI-induced arthralgia was durably controlled through a Mediterranean plant-forward diet and daily physical activity guided by continuous glucose monitoring. We posit that diet and a lifestyle inclusive of daily physical activity constitute a low-cost, low-risk, and potentially high-reward strategy for controlling common AI-induced musculoskeletal symptoms and that more investigation in this arena, including well-designed randomized trials, is warranted.

oncology
New approaches to nanoparticle sample fabrication for atom probe tomography.

P. Felfer,Tong Li,Tong Li,K. Eder,Henning Galinski,A. Magyar,David C. Bell,G.D.W. Smith,Norbert Kruse,S. Ringer,J. Cairney

DOI: https://doi.org/10.1016/j.ultramic.2015.04.014

IF: 2.994

2015-12-01

Ultramicroscopy

Abstract:
Developing pioneering surgery in Europe: percutaneous aortic valve replacement. Interview by Mark Nicholls.

J. Kovac

DOI: https://doi.org/10.1161/CIRCULATIONAHA.107.183873

2007-05-01

Abstract:
Soft tissue disorders of the upper extremities.

P. H. Travers

1988-04-01

Occupational Medicine

Abstract:The incidence of occupationally induced cumulative trauma disorders of the upper extremities appears to be in the rise in the United States. Such disorders account for a significant amount of human suffering, loss of productivity and economic burden. The author defines the problem and its etiology, reviews appropriate screening procedures and the diagnosis, summarizes treatment approaches, and concludes with a discussion of preventative measures that should be considered.
Current and future advances in practice: aromatase inhibitor–induced arthralgia

Sara Kim,Nan Chen,Pankti Reid

DOI: https://doi.org/10.1093/rap/rkae024

2024-01-01

Rheumatology Advances in Practice

Abstract:Abstract Aromatase inhibitors (AIs) have shown great success as adjuvant therapy for post-menopausal women with hormone receptor–positive breast cancers. AI-induced arthralgia (AIA) is a frequent AI toxicity contributing to non-adherence and discontinuation. This review aims to understand current knowledge of AIA. The mean incidence of AIA was 39.1% and the mean discontinuation of AI therapy due to AIA was 9.3%. Most of the AIAs were non-inflammatory. A shorter time since the last menstrual period and pre-existing joint pain were risk factors. Vitamin D3 supplementation may be a preventative measure and treatment with duloxetine, acupuncture and/or exercise is supported by large randomized controlled trials. There was consistent improvement in AIAs with switching to an alternate AI, and this could additionally allow continuation of cancer treatment with AI. Further research is needed to identify predictive biomarkers, better characterize AIA subcategories and study more reliable therapeutic options.
Aromatase Inhibitors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects

Sara Tenti,Pierpaolo Correale,Sara Cheleschi,Antonella Fioravanti,Luigi Pirtoli

DOI: https://doi.org/10.3390/ijms21165625

2020-08-06

Abstract:Aromatase inhibitors (AIs) have radically changed the prognosis of hormone receptor positive breast cancer (BC) in post-menopausal women, and are a mainstay of the adjuvant therapy for BC after surgery in place of, or following, Tamoxifen. However, AIs aren't side effect-free; frequent adverse events involve the musculoskeletal system, in the form of bone loss, AI-associated arthralgia (AIA) syndrome and autoimmune rheumatic diseases. In this narrative review, we reported the main clinical features of these three detrimental conditions, their influence on therapy adherence, the possible underlying molecular mechanisms and the available pharmacological and non-pharmacological treatments. The best-known form is the AIs-induced osteoporosis, whose molecular pathway and therapeutic possibilities were extensively investigated in the last decade. AIA syndrome is a high prevalent joint pain disorder which often determines a premature discontinuation of the therapy. Several points still need to be clarified, as a universally accepted diagnostic definition, the pathogenetic mechanisms and satisfactory management strategies. The association of AIs therapy with autoimmune diseases is of the utmost interest. The related literature has been recently expanded, but many issues remain to be explored, the first being the molecular mechanisms.
Polar codes : A pipelined implementation

E. Arıkan

Abstract:Polar codes are a class of codes that can achieve the capacity of binary-input memoryless channels with certain symmetries. These codes have a recursive structure tha t make it possible to encode and decode them within complexity O(N log N) for a code of block length N . This paper presents pipelined architectures with identical modules that are useful for low-complexity implementation of polar codes both in hardware and software. The uniform structure of the modules in the design make it possible to trade complexity for time in hardware implementations.
Developing Combination Cancer Therapy from Ontology Fingerprint Derived Gene Network

W. J. Zheng,Guocai Chen,L. Tsoi,T. Qin,Chia-Hua Chang,G. Bartholomeusz,Hua Xu

Abstract:
Online pain neuroscience education and graded exposure to movement in breast cancer survivors: protocol of a randomized controlled trial

Patricia Martínez-Miranda,María Jesús Casuso-Holgado,Cristina García-Muñoz,María Jesús Muñoz-Fernández,José Jesús Jiménez-Rejano

DOI: https://doi.org/10.3389/fmed.2024.1355964

IF: 3.9

2024-02-28

Frontiers in Medicine

Abstract:Introduction Cancer-related chronic pain is an important sequelae that damages the quality of life of breast cancer survivors. Pain neuroscience education and graded exposure to movement are therapeutic tools that have been shown to be effective in the management of chronic pain in other populations. However, there are no previous studies that combine them after breast cancer. Objective To evaluate the effectiveness of an online physiotherapy focused-person program which combines pain neuroscience education and graded exposure to movement for quality of life improvement in breast cancer survivors. Methodology This protocol is a randomized controlled trial with a sample size of 40 breast cancer survivors with pain in the last 6 months. Participants will be allocated to the experimental or control group using a fixed size block randomization method. The evaluator and statistician will be blinded to participant allocation. Participants in the experimental group will receive a 12-week intervention based on pain neuroscience education and therapeutic yoga as a graded exposure to movement exercise; participants in the control group will continue with their usual cancer-related symptoms care. Both groups will receive an education booklet. The main outcome will be quality of life, measured by the Functional Assessment of Cancer Therapy – Breast (FACT–B+4); secondary, four outcomes related to pain experience (catastrophising, self-efficacy, kinesiophobia and fear-avoidance behaviors) will be also assessed. All variables will be assessed by two blinded evaluators at four timepoints. A mixed-model analyses of variance ANOVA (2 × 4) will be used to study the effects of the treatment on the dependent variables. All statistical tests will be performed considering a confidence interval of 95%. SPSS program will be used for the data analysis. Discussion This research is expected to contribute to breast cancer rehabilitation field. The proposed intervention is also expected to improve self-care skills related to chronic pain and to empower women regarding the management of their symptoms and quality of life. Clinical trial registration: https://clinicaltrials.gov/ , NCT04965909.

medicine, general & internal

[Studies on retrograde amnesia in petit mal].

Journal Watch of Neural systems subserving valence and arousal during the experience of induced emotions

Acupuncture for Treatment of Arthralgia Secondary to Aromatase Inhibitor Therapy in Women with Early Breast Cancer: Pilot Study

Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients

Yoga versus massage in the treatment of aromatase inhibitor-associated knee joint pain in breast cancer survivors: a randomized controlled trial

Multiple Sclerosis Therapy

Suppressing effects of caffeine on postextrasystolic potentiation in papillary muscles of guinea pigs.

Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer

Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial

Aromatase inhibitor musculoskeletal toxicity (AIMT) in patients (pts) with early breast cancer (EBC): Prevalence, management, and association with non-adherence to AI.

Progressive relaxation training in patients with breast cancer receiving aromatase inhibitor therapy-randomized controlled trial

Aromatase inhibitor-induced arthralgia ameliorated by Mediterranean diet and active lifestyle guided by continuous glucose monitoring: a case report and review of the literature

New approaches to nanoparticle sample fabrication for atom probe tomography.

Developing pioneering surgery in Europe: percutaneous aortic valve replacement. Interview by Mark Nicholls.

Soft tissue disorders of the upper extremities.

Current and future advances in practice: aromatase inhibitor–induced arthralgia

Aromatase Inhibitors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects

Polar codes : A pipelined implementation

Developing Combination Cancer Therapy from Ontology Fingerprint Derived Gene Network

Online pain neuroscience education and graded exposure to movement in breast cancer survivors: protocol of a randomized controlled trial